Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

GLP2-2G-XTEN: a pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn's disease model.

Alters SE, McLaughlin B, Spink B, Lachinyan T, Wang CW, Podust V, Schellenberger V, Stemmer WP.

PLoS One. 2012;7(11):e50630. doi: 10.1371/journal.pone.0050630. Corrected and republished in: PLoS One. 2013;8(6). doi: 10.1371/annotation/5c7138bd-5602-466d-8daf-e75e0b7d7fdb.

2.

GLP2-2G-XTEN: a pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn's. PLoS One. 2012; 7(11): e50630.

Alters SE, McLaughlin B, Spink B, Lachinyan T, Wang CW, Podust V, Schellenberger V, Stemmer WP.

PLoS One. 2013 Jun 10;8(6). doi: 10.1371/annotation/5c7138bd-5602-466d-8daf-e75e0b7d7fdb.

3.

Extension of in vivo half-life of biologically active peptides via chemical conjugation to XTEN protein polymer.

Podust VN, Sim BC, Kothari D, Henthorn L, Gu C, Wang CW, McLaughlin B, Schellenberger V.

Protein Eng Des Sel. 2013 Nov;26(11):743-53. doi: 10.1093/protein/gzt048.

4.

Multivalent antiviral XTEN-peptide conjugates with long in vivo half-life and enhanced solubility.

Ding S, Song M, Sim BC, Gu C, Podust VN, Wang CW, McLaughlin B, Shah TP, Lax R, Gast R, Sharan R, Vasek A, Hartman MA, Deniston C, Srinivas P, Schellenberger V.

Bioconjug Chem. 2014 Jul 16;25(7):1351-9. doi: 10.1021/bc500215m.

6.

Glucagon-like peptide-2 and mouse intestinal adaptation to a high-fat diet.

Baldassano S, Amato A, Cappello F, Rappa F, Mulè F.

J Endocrinol. 2013 Mar 15;217(1):11-20. doi: 10.1530/JOE-12-0500.

7.

Gcg-XTEN: an improved glucagon capable of preventing hypoglycemia without increasing baseline blood glucose.

Geething NC, To W, Spink BJ, Scholle MD, Wang CW, Yin Y, Yao Y, Schellenberger V, Cleland JL, Stemmer WP, Silverman J.

PLoS One. 2010 Apr 14;5(4):e10175. doi: 10.1371/journal.pone.0010175.

8.

Acute effects of the glucagon-like peptide 2 analogue, teduglutide, on intestinal adaptation in short bowel syndrome.

Thymann T, Stoll B, Mecklenburg L, Burrin DG, Vegge A, Qvist N, Eriksen T, Jeppesen PB, Sangild PT.

J Pediatr Gastroenterol Nutr. 2014 Jun;58(6):694-702. doi: 10.1097/MPG.0000000000000295.

PMID:
24399211
9.

A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner.

Schellenberger V, Wang CW, Geething NC, Spink BJ, Campbell A, To W, Scholle MD, Yin Y, Yao Y, Bogin O, Cleland JL, Silverman J, Stemmer WP.

Nat Biotechnol. 2009 Dec;27(12):1186-90. doi: 10.1038/nbt.1588.

PMID:
19915550
10.

XTEN-annexin A5: XTEN allows complete expression of long-circulating protein-based imaging probes as recombinant alternative to PEGylation.

Haeckel A, Appler F, Figge L, Kratz H, Lukas M, Michel R, Schnorr J, Zille M, Hamm B, Schellenberger E.

J Nucl Med. 2014 Mar;55(3):508-14. doi: 10.2967/jnumed.113.128108.

11.

Insulin-like growth factor 1: common mediator of multiple enterotrophic hormones and growth factors.

Bortvedt SF, Lund PK.

Curr Opin Gastroenterol. 2012 Mar;28(2):89-98. doi: 10.1097/MOG.0b013e32835004c6. Review.

12.

Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease.

Buchman AL, Katz S, Fang JC, Bernstein CN, Abou-Assi SG; Teduglutide Study Group..

Inflamm Bowel Dis. 2010 Jun;16(6):962-73. doi: 10.1002/ibd.21117.

PMID:
19821509
13.

Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease.

Abad C, Martinez C, Juarranz MG, Arranz A, Leceta J, Delgado M, Gomariz RP.

Gastroenterology. 2003 Apr;124(4):961-71.

PMID:
12671893
14.

Teduglutide in intestinal adaptation and repair: light at the end of the tunnel.

Mardini HE, de Villiers WJ.

Expert Opin Investig Drugs. 2008 Jun;17(6):945-51. doi: 10.1517/13543784.17.6.945 . Review.

PMID:
18491995
15.

Responsiveness of IGF-I and IGFBP-3 to therapeutic intervention in children and adolescents with Crohn's disease.

Beattie RM, Camacho-Hübner C, Wacharasindhu S, Cotterill AM, Walker-Smith JA, Savage MO.

Clin Endocrinol (Oxf). 1998 Oct;49(4):483-9.

PMID:
9876346
16.

Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-human serum albumin fusion protein in mice.

Melder RJ, Osborn BL, Riccobene T, Kanakaraj P, Wei P, Chen G, Stolow D, Halpern WG, Migone TS, Wang Q, Grzegorzewski KJ, Gallant G.

Cancer Immunol Immunother. 2005 Jun;54(6):535-47.

PMID:
15592670
17.

Natalizumab for induction of remission in Crohn's disease.

Macdonald JK, McDonald JW.

Cochrane Database Syst Rev. 2006 Jul 19;(3):CD006097. Review. Update in: Cochrane Database Syst Rev. 2007;(1):CD006097.

PMID:
16856112
18.

Oral mesalazine for the treatment of Crohn's disease: clinical efficacy with respect to pharmacokinetic properties.

Tromm A, Griga T, May B.

Hepatogastroenterology. 1999 Nov-Dec;46(30):3124-35. Review.

PMID:
10626173
20.

Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV.

Drucker DJ, Shi Q, Crivici A, Sumner-Smith M, Tavares W, Hill M, DeForest L, Cooper S, Brubaker PL.

Nat Biotechnol. 1997 Jul;15(7):673-7.

PMID:
9219272
Items per page

Supplemental Content

Support Center